Y-mAbs Therapeutics Inc (NASDAQ:YMAB)
| 14.50 Delayed Data As of 3:59pm ET |  +0.54 / +3.87%Today’s Change | 6.50 Today|||52-Week Range 30.16 | -10.55% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $610.3M |
Company Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Contact Information
Y-mAbs Therapeutics, Inc. 230 Park Avenue New York New York 10169-0005 |
Employees
Shareholders
| Mutual fund holders | 46.54% |
| Individual stakeholders | 21.76% |
| Other institutional | 13.36% |
Top Executives
| Thomas Gad | President, Chief Executive Officer & Director |
| Joris Wiel Jan Wilms | Chief Operating Officer & Senior Vice President |
| Bo Kruse | CFO, Secretary. Treasurer & Executive VP |
| Torben Lund-Hansen | Chief Technology Officer & Senior Vice President |
| Steen Lisby | Chief Scientific Officer & Senior Vice President |
